Prominent Acute Agitation And Aggression Treatment Market Trend for 2025: Innovative Sublingual Film Igalmi (Dexmedetomidine) Revolutionizes Acute Agitation Treatment Market

What Are the Projected Growth and Market Size Trends for the Acute Agitation And Aggression Treatment Market?
In the past few years, there has been significant growth in the market size for acute agitation and aggression treatments. It's projected to increase from $5.72 billion in 2024 to $6.05 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this growth during the historic period includes advances in pharmacology, increased clinical research, regulatory go-aheads, an escalating number of acute agitation and aggression incidents, and a heightened awareness about mental health.

Anticipation for a robust expansion in the acute agitation and aggression treatment market is high over the coming years. The market is projected to develop at a compound annual growth rate (CAGR) of 6.4%, reaching $7.77 billion by 2029. The increase during the forecasted period can be credited to factors such as an aging population, enhancements in healthcare infrastructure, increased investment in the pharmaceutical industry, the rise of home-based care, and improved disposable income. Foreseen trends during this period include the use of non-pharmacological interventions, precision medicine, AI and predictive analytics, community-based support, as well as industry collaborations.

What Is Driving the Growth Trajectory of the Acute Agitation And Aggression Treatment Market?
The surge in dementia cases is forecasted to fuel the expansion of the market for acute agitation and aggression treatment. Dementia is a term used to describe conditions involving difficulties with memory, cognition, and performing daily tasks. One common symptom seen in dementia patients is agitation, which can take the form of restlessness, repetitive motions, or frequent hand movements. Treatments for acute agitation and aggression play a vital role in managing dementia, helping to decrease the threat of damaging symptoms, enhance the patient's quality of life, and treat the root cause of agitation. For example, statistics from the Australian Institute of Health and Welfare in February 2023 indicated that there were an estimated 401,300 Australians living with dementia in 2022, a number that is projected to more than double to 849,300 by 2058. As such, the rising incidence of dementia is spurring the growth of the acute agitation and aggression treatment market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13078&type=smp

Which Leading Companies Are Shaping the Growth of the Acute Agitation And Aggression Treatment Market?
Major companies operating in the acute agitation and aggression treatment market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc

What Are the Major Trends Shaping the Acute Agitation And Aggression Treatment Market?
Key players in the acute agitation and aggression treatment market are advancing their offerings by devising innovative products like IGALMI (dexmedetomidine), eliciting a novel mode of treatment for individuals suffering from agitated states correlated with schizophrenia or bipolar disorder. IGALMI (dexmedetomidine), as a sublingual film, is employed in managing acute agitation in adults allied with schizophrenia or bipolar I or II disorder. For example, BioXcel Therapeutics Inc., a biopharmaceutical organization based in the US, secured approval for IGALMI (dexmedetomidine) from the Food and Drug Administration in April 2022. This course of treatment exhibits fast-acting properties, demonstrating efficacy within minutes, albeit its effects are short-lived, enduring up to approximately 2 hours. However, it has the potential to substantially enhance current treatments for a severe or life-threatening condition.

What Are the Key Segments of the Acute Agitation And Aggression Treatment Market?
The acute agitation and aggression treatment market covered in this report is segmented -

1) By Treatment Approach: Behavioral Approaches, Environmental Interventions, Pharmacologic Approaches
2) By Drug Class: Anti-Psychotics, Benzodiazepines, Other Drug Classes
3) By Route of Administration: Oral, Intramuscular, Other Routes of Administrations
4) By Indication: Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-Induced Agitation And Aggression, Alcohol Withdrawal, Other Indications
5) By End User: Hospitals And Ambulatory Surgical Centers, Psychiatric Care Facilities, Other End Users

Subsegments:
1) By Box Style: Standard Box Action Cameras, Modular Box Action Cameras
2) By Cube Style: Compact Cube Action Cameras, Cube Cameras with Integrated Mounts
3) By Bullet Style: Long, Cylindrical Action Cameras, Mountable Bullet Cameras
4) By Periscope & 360°: 360-Degree Cameras, Periscope Cameras
5) By Other Types: Wearable Action Cameras, Drone Action Cameras, Specialty Action Cameras

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/acute-agitation-and-aggression-treatment-global-market-report

Which Region Dominates the Acute Agitation And Aggression Treatment Market?
The countries covered in the acute agitation and aggression treatment market market report include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Is Covered In The Acute Agitation And Aggression Treatment Global Market Report?

- Market Size Analysis: Analyze the Acute Agitation And Aggression Treatment Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Acute Agitation And Aggression Treatment Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Acute Agitation And Aggression Treatment Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Acute Agitation And Aggression Treatment Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13078

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.